Immediate intraoperative detrusor muscle status at primary transurethral resection of bladder tumour: a prospective, blinded, paired cohort, feasibility study using fluorescence confocal microscopy ( IB1 ‐ LaserComplete study)
Open Access
- 13 August 2026
- journal article
- Published by Wiley in BJU International
- Vol. 138 (4) , 705-713
Abstract
Objectives: To evaluate ex vivo fluorescence confocal microscopy (FCM) for immediate detrusor muscle (DM) assessment during primary transurethral resection of bladder tumour (TURBT). Patients and Methods: This prospective, blinded, paired‐cohort feasibility study enrolled consecutive patients undergoing primary TURBT for suspected non‐muscle‐invasive bladder cancer between September 2024 and September 2025 (IB1‐LaserComplete study; International Standard Randomised Controlled Trial Number Register [ISRCTN]16114765). Ex vivo FCM generates immediate high‐resolution digital images of fresh tissue, enabling immediate DM assessment. Intraoperative ex vivo FCM imaging of en face tumour base specimens was performed using the Histolog® scanner (SamanTree Medical SA, Lausanne, Switzerland). DM status was reported by a blinded uro‐pathologist and urologist. Formalin‐fixed histopathology served as the reference standard. The primary outcome was technical feasibility, defined as acquisition of an interpretable FCM image. Secondary outcomes included exploratory diagnostic performance, inter‐observer agreement and time to confirmation of DM status. Results: A total of 34 patients were recruited and 30 had evaluable paired specimens. DM was absent in 13% (four of 30). FCM was sufficient for determining DM status in all patients (100%; 30 of 30). Sensitivity, specificity, positive predictive value, negative predictive value (NPV) were 42% (95% confidence interval [CI] 26–61%), 100% (95% CI 51–100%), 100% (95% CI 74–100%), and 21% (95% CI 9–43%), respectively. Inter‐observer agreement between the uro‐pathologist and urologist was high at 83% (κ = 0.72, 95% CI 0.47–0.97). The median (interquartile range) time to confirm DM status was 5.4 (4.95–5.39) min vs 11 (7–13.8) days using standard histopathology. Conclusion: Fluorescence confocal microscopy is feasible for rapid intraoperative imaging of TURBT specimens and demonstrates excellent specificity for detection of DM. However, its low sensitivity and NPV preclude use as a stand‐alone tool to exclude DM intraoperatively. Based on these findings, FCM should not guide intraoperative decision making outside research settings.Keywords
Funding Information
- Urology Foundation (WSSY.NEP032)
This publication has 25 references indexed in Scilit:
- RESECT: A Randomised Controlled Trial of Audit and Feedback in Non–muscle-invasive Bladder Cancer SurgeryEuropean Urology, 2025
- IP8-FLUORESCE: A Prospective Paired Cohort Study Evaluating the Diagnostic Accuracy of Fluorescence Confocal Microscopy for Real-time Assessment of Surgical Margins in Radical ProstatectomyEuropean Urology, 2025
- The Hawthorne Effect: Quality and Outcomes in Neurosurgery2023
- Photodynamic Diagnosis-guided Transurethral Resection of Bladder Tumour in Participants with a First Suspected Diagnosis of Intermediate- or High-risk Non–muscle-invasive Bladder Cancer: Cost-effectiveness Analysis Alongside a Randomised Controlled TrialEuropean Urology Open Science, 2023
- Potential Carbon Savings with Day-case Compared to Inpatient Transurethral Resection of Bladder Tumour Surgery in England: A Retrospective Observational Study Using Administrative DataEuropean Urology Open Science, 2023
- En Bloc Versus Conventional Transurethral Resection of Bladder Tumors: A Single-center Prospective Randomized Noninferiority TrialEuropean Urology Oncology, 2022
- Holmium Laser En-bloc Resection Versus Conventional Transurethral Resection of Bladder Tumors for Treatment of Non–muscle-invasive Bladder Cancer: A Randomized Clinical TrialEuropean Urology Focus, 2021
- A simple formula for the calculation of sample size in pilot studiesJournal of Clinical Epidemiology, 2015
- Detrusor Muscle in the First, Apparently Complete Transurethral Resection of Bladder Tumour Specimen Is a Surrogate Marker of Resection Quality, Predicts Risk of Early Recurrence, and Is Dependent on Operator ExperienceEuropean Urology, 2010
- Predicting Recurrence and Progression in Individual Patients with Stage Ta T1 Bladder Cancer Using EORTC Risk Tables: A Combined Analysis of 2596 Patients from Seven EORTC TrialsEuropean Urology, 2006